DMK CEO, Ebrahim (Eboo) Versi, MD, PhD, named CEO and Chairman of the combined company
Combined company will have commercial products and a library of development candidates, including two clinical stage programs
DPI-125, the lead development program, is a clinical stage therapeutic under investigation for the treatment of opioid use disorder
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its merger with DMK Pharmac